Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Regulatory Flexibility On Display In Review Of Innovative Agents

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Regulatory flexibility is the backbone of FDA’s success in efficiently reviewing new drugs and biologics, especially on the frontiers of unmet medical needs, Pharmaceutical Approvals Monthly’s 2011 series of drug review profiles shows.

Advertisement

Related Content

FDA Considers Toxicity Profiles As Meeting Unmet Need In Melanoma
Novartis Sees Targeted Combinations As Wave Of The Future In Oncology
FDA Role In Risk Management Should Be “Broad Societal Decision,” Hamburg Says
Innovation Pays: Priority Drugs Drove Novel 2011 Approvals To New Heights
Innovation Pays: Priority Drugs Drove Novel 2011 Approvals To New Heights
Remember The Basics: Dosing, Placebo Issues Recur In FDA Reviews
FDA Initiatives To Expedite Reviews Pay Off In FY’11 Approvals
Out Of The Shadow Of REMS: FDA Review Documents Show Emerging Importance Of Post-Marketing Requirements

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS004884

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel